Initiates Coverage on InspireMD (NYSE:NSPR) initiated coverage on shares of InspireMD (NYSE:NSPRFree Report) in a report released on Wednesday. The brokerage issued a sell rating on the stock.

InspireMD Price Performance

NYSE:NSPR opened at $2.52 on Wednesday. The firm has a 50-day moving average of $2.35 and a two-hundred day moving average of $2.50. The stock has a market cap of $62.82 million, a P/E ratio of -3.32 and a beta of 0.95. InspireMD has a 1-year low of $1.81 and a 1-year high of $3.85.

InspireMD (NYSE:NSPRGet Free Report) last issued its quarterly earnings results on Tuesday, May 14th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.06). InspireMD had a negative return on equity of 55.12% and a negative net margin of 350.35%. The company had revenue of $1.51 million for the quarter, compared to the consensus estimate of $1.38 million. During the same period in the previous year, the business posted ($0.53) EPS. As a group, equities analysts expect that InspireMD will post -0.82 earnings per share for the current year.

Hedge Funds Weigh In On InspireMD

An institutional investor recently bought a new position in InspireMD stock. McKinley Carter Wealth Services Inc. bought a new position in InspireMD, Inc. (NYSE:NSPRFree Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 10,000 shares of the company’s stock, valued at approximately $28,000. 44.78% of the stock is owned by institutional investors and hedge funds.

InspireMD Company Profile

(Get Free Report)

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.

Featured Stories

Receive News & Ratings for InspireMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD and related companies with's FREE daily email newsletter.